American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1
复制标题
DOI：
10.1002/art.41734
复制
发表时间：
2021-05-24
影响因子：
13.3
通讯作者：
Mikuls, Ted R.
中科院分区：
文献类型：
--
作者：
Curtis, Jeffrey R.;Johnson, Sindhu R.;Mikuls, Ted R.
目的为风湿科医生提供风湿和肌肉骨骼疾病（RMD）患者使用2019冠状病毒病（COVID-19）疫苗的指导。方法组建一个由9名风湿科医生/免疫学家、2名传染病专家和2名公共卫生医生组成的工作组。在就范围问题达成一致后，创建了一份证据报告，总结了有关COVID-19疫苗有效性和安全性的已发表文献和公开数据，以及其他疫苗在RMD患者中的文献。工作组成员使用改良的德尔菲法和兰德/加州大学洛杉矶适当方法，通过2次会议的改进和迭代，对9分数值评分系统上的共识声明草案的一致性进行评分。结果尽管缺乏直接证据，工作组还是制定了74份指导声明草案，并达成共识，为RMD患者使用COVID-19疫苗提供指导，并就疫苗接种前后免疫调节治疗的使用和时机提供建议。结论这些指导声明，在临床数据有限的情况下制定的，旨在为风湿病医疗保健提供者提供如何最好地使用COVID-19疫苗的指导，并促进RMD患者疫苗接种策略的实施。
Objective To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID-19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).Methods A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.Results Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.Conclusion These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.